65. Primary immunodeficiency Clinical trials / Disease details
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04691622 (ClinicalTrials.gov) | October 26, 2020 | 28/12/2020 | Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts | Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts | Viral Infection;Hematopoietic Stem Cell Transplantation (HSCT);Primary Immunodeficiency Disorders (PID) | Biological: Norovirus -specific T-cell (NST) therapy | Children's National Research Institute | NULL | Recruiting | 3 Months | 80 Years | All | 48 | Phase 1 | United States |